Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7066537 | 0.74 | TDP1 (0.41) | CYP3A4TDP1ESR1ESR2TSHR | |
| SCHEMBL518737 | 0.73 | TDP1 (0.60) | CYP3A4TDP1CYP2A6SMN1; SMN2ESR1 | |
| SCHEMBL2329641 | 0.72 | CYP3A4 (0.45) | CYP3A4TDP1LOXL2TAAR1HTR2A | |
| SCHEMBL27897907 | 0.70 | CYP3A4 (0.43) | CYP3A4TDP1LOXL2TAAR1HTR2A | |
| SCHEMBL28978394 | 0.69 | CYP3A4 (0.36) | CYP3A4TDP1CYP2C19TSHR | |
| SCHEMBL10024968 | 0.68 | CYP3A4 (0.41) | CYP3A4TDP1LOXL2TAAR1HTR2A | |
| Hydrochloric Acid SCHEMBL3640613 | 0.68 | CYP3A4 (0.41) | CYP3A4TDP1LOXL2TAAR1HTR2A | |
| SCHEMBL27634735 | 0.68 | CYP3A4 (0.41) | CYP3A4TDP1LOXL2TAAR1HTR2A | |
| SCHEMBL27902527 | 0.68 | CYP3A4 (0.41) | CYP3A4TDP1LOXL2TAAR1HTR2A | |
| SCHEMBL27769845 | 0.68 | CYP3A4 (0.41) | CYP3A4TDP1LOXL2TAAR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030120122-A1 | Chiral diphenyldiphosphines and d-8 metal complexes thereof | PUGIN BENOIT (CH) | 2003-06-26 | — | — | US | disclosed |
| EP-1002801-B1 | Chiral diphenyldiphosphines and d-8 metal complexes thereof | SOLVIAS AG (CH) | 2003-06-18 | — | — | EP | disclosed |
| US-6515183-B2 | Hydrogenation catalyst | SOLVIAS AG (CH) | 2003-02-04 | — | — | US | disclosed |
| US-20010056210-A1 | Chiral diphenyldiphosphines and d-8 metal complexes thereof | PUGIN BENOIT (CH) | 2001-12-27 | — | — | US | disclosed |
| US-6281390-B1 | COMPLEXES WITH METAL ARE USED AS CATALYSTS FOR THE ENANTIOSELECTIVE HYDROGENATION OF PROCHIRAL ORGANIC COMPOUNDS | SOLVIAS AG (CH) | 2001-08-28 | — | — | US | disclosed |
| EP-1002801-A1 | Chiral diphenyldiphosphines and d-8 metal complexes thereof | Solvias AG (CH) | 2000-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120122-A1 | Chiral diphenyldiphosphines and d-8 metal complexes thereof | CCNH, DBH, FTH1 | CYP3A4 2788/4885TDP1 3670/4885LOXL2 2883/4885 |
| US-20010056210-A1 | Chiral diphenyldiphosphines and d-8 metal complexes thereof | CCNH, OCIAD2, FTH1 | CYP3A4 2994/4885TDP1 3505/4885LOXL2 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.